Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31000711 | 1.00 | CASP1 (0.43) | CASP1POLBCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL22892445 | 0.93 | POLB (0.45) | CASP1POLBCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL4249277 | 0.88 | KMT2A (0.43) | POLBCYP1A2CYP2C19FABP5FABP7 | |
| SCHEMBL3788777 | 0.88 | KMT2A (0.43) | POLBCYP1A2CYP2C19FABP5FABP7 | |
| SCHEMBL3789335 | 0.88 | KMT2A (0.43) | POLBCYP1A2CYP2C19FABP5FABP7 | |
| SCHEMBL3793423 | 0.88 | KMT2A (0.43) | POLBCYP1A2CYP2C19FABP5FABP7 | |
| SCHEMBL3783542 | 0.88 | KMT2A (0.43) | POLBCYP1A2CYP2C19FABP5FABP7 | |
| SCHEMBL25968728 | 0.87 | FABP5 (0.43) | CASP1FABP5FABP7KMT2AMDM2 | |
| SCHEMBL12863461 | 0.86 | BACE1 (0.42) | CASP1POLBCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL4612189 | 0.84 | FABP5 (0.46) | POLBFABP5FABP7KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4441070-A1 | MODIFIED AMATOXINS AND USES THEREOF | The University of British Columbia (CA) | 2024-10-09 | — | — | EP | disclosed |
| CN-110615826-B | Cosmetic composition and pharmaceutical composition | 因科斯医药公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023097407-A1 | MODIFIED AMATOXINS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-06-08 | — | — | WO | disclosed |
| US-10618874-B2 | Compounds, cosmetic composition and pharmaceutical composition comprising the same | INCOSPHARM CORPORATION (KR) | 2020-04-14 | — | — | US | disclosed |
| CN-110615826-A | Novel compound, cosmetic composition and pharmaceutical composition containing same | 因科斯医药公司 | 2019-12-27 | — | — | CN | disclosed |
| US-6936586-B1 | Synthetic IL-10 analogues | STEENO RESEARCH GROUP A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-6716574-B2 | DIAGNOSING AND DEVELOPING VACCINES AGAINST LYME'S DISEASE; OUTER SURFACE PROTEIN C (OSPC); IMMUNOASSAYS | DAKO A/S (DK) | 2004-04-06 | — | — | US | disclosed |
| US-20030138866-A1 | Novel Osp-C derived peptide fragments | STATENS SERUM INSTITUT | 2003-07-24 | — | — | US | disclosed |
| EP-0896583-B1 | USE OF PEPTIDE FRAGMENTS DERIVED FROM OSP-C FOR DIAGNOSTIC METHODS | DAKO AS (DK) | 2003-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618874-B2 | Compounds, cosmetic composition and pharmaceutical composition comprising the same | TYR, MITF, TFEB | CASP1 3026/4885POLB 2451/4885CYP1A2 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.